Why PreludeDx’s second FDA breakthrough device designation matters for precision diagnostics
Breast cancer care needs sharper radiation decisions. PreludeDx’s AidaBREAST now faces the harder test of validation, adoption and access.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Can PreludeDx and Quanterix turn AidaBREAST into a new standard for radiation therapy decisions
See why AidaBREAST could reshape breast cancer radiation decisions and put spatial proteomics closer to routine oncology use.